Phaseline

Companies › Denali Therapeutics

Denali Therapeutics: clinical trials, targets and expected readouts

7 active drug programs in 8 registered trials: 6 Phase 1, 2 Phase 2; Neurology, Metabolic and endocrine; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
BIIB122
LRRK2 kinase inhibitor
LRRK2Phase 2Parkinson DiseaseMar 2027
tividenofusp alfa (DNL310)
CNS-penetrant iduronate 2-sulfatase enzyme replacement therapy
IDSPhase 2Mucopolysaccharidosis IIDec 2027
DNL593
GRN gene modifier
–Phase 1Frontotemporal DementiaDec 2026
DNL628
LRRK2 kinase inhibitor
–Phase 1Alzheimer Disease, Early OnsetFeb 2027
DNL952
Pompe disease treatment
–Phase 1Late-onset Pompe DiseaseAug 2028
DNL921–Phase 1Alzheimer's DiseaseApr 2030
DNL126
Gene therapy for mucopolysaccharidosis type IIIA
–Phase 1Mucopolysaccharidosis Type IIIAJul 2032

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05262023DNL593Phase 1Frontotemporal DementiaNeurologyDec 2026
NCT07328451DNL628Phase 1Alzheimer Disease, Early OnsetNeurologyFeb 2027
NCT06602193BIIB122Phase 2Parkinson DiseaseNeurologyMar 2027
NCT05371613tividenofusp alfa (DNL310)Phase 2Mucopolysaccharidosis IIMetabolic and endocrineDec 2027
NCT07354724DNL952Phase 1Late-onset Pompe DiseaseMetabolic and endocrineAug 2028
NCT07758595DNL921Phase 1Alzheimer's DiseaseNeurologyApr 2030
NCT04251026tividenofusp alfa (DNL310)Phase 1Mucopolysaccharidosis IIMetabolic and endocrineFeb 2031
NCT06181136DNL126Phase 1Mucopolysaccharidosis Type IIIAMetabolic and endocrineJul 2032

From the company's SEC filings

Cash and short-term investments of $516m on 2026-09-30; operating cash outflow about $464m a year; runway about 13 months at that burn, to Nov 2027; 1 of 2 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Regulatory dates the company has stated

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 4 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

IDS (1) LRRK2 (1)

Companies with the same targets

Takeda GC Biopharma REGENXBIO Syntara Neuron23 Eli Lilly

Companies built like this

MediciNova Beijing Suncadia Pharmaceuticals Neuron23 Syntara Solid Biosciences

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.